Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Plasma kallikrein inhibitors for on-demand treatment
20 evidence topics · 11 sources
Sebetralstat: FDA approval date
Sebetralstat: dosing and maximum daily dose
Sebetralstat: dose modification for CYP3A4 inhibitors and inducers and hepatic impairment
KONFIDENT: design and results as described in the FDA label
KONFIDENT: published primary and key secondary endpoints
“A total of 136 participants were assigned to one of six trial sequences, with 110 treating 264 attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sebetralstat: pooled analysis of the phase 2 and phase 3 trials
“377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median (interquartile range) time to treatment was 32.5 min (8.0–94.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to beginning of symptom relief was 1.6 h (0.8–7.0) and 1.8 h (1.0–4.3) with sebetralstat 300 mg and 600 mg, respectively, and 8.3 h (1.5 to >12) with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KONFIDENT-S: interim long-term safety and effectiveness
“This analysis evaluated long-term safety and effectiveness of sebetralstat in KONFIDENT-S (NCT05505916), an ongoing, 2-year, open-label extension study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At data cutoff (January 31, 2024), 84 participants (mean age: 35.9 years; 14.3% <18 years; 64.3% female) treated 640 attacks with sebetralstat (84% of total attacks); the median (interquartile range [IQR]) number of attacks per participant was 5 (2-8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median (IQR) time from attack onset to treatment was 9 (1-69) minutes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related TEAEs occurred in 8 participants (9.5%); none were serious.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to beginning of symptom relief (allowing for missing data entries between consecutive time points) was 1.68 (0.79-3.89) hours, to reduction in severity 6.57 (1.61 to >12) hours, and to complete attack resolution 21.02 (7.22 to >24) hours.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KONFIDENT-S: breakthrough attacks in participants receiving long-term prophylaxis
“The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KONFIDENT-S: laryngeal and abdominal attacks
“This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2‐year, open‐label extension KONFIDENT‐S study (NCT05505916).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median (IQR) time to treatment: 11.5 min (1.0–34.0) and 20.0 min (1.0–61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76–3.02) and 1.27 h (0.76–3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conventional on‐demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sebetralstat: guideline statement
“Sebetralstat, an oral plasma kallikrein inhibitor, was recently approved by the United States Food and Drug Administration (FDA) as an ODT for HAE, based on the findings of the KONFIDENT study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only oral ODT available is sebetralstat and the dose is 2 300 mg tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide: boxed warning for anaphylaxis
Ecallantide: FDA-approved indication and dosing
Ecallantide: incidence of anaphylaxis in clinical studies
EDEMA4 and EDEMA3: design and results as described in the FDA label
Ecallantide compared with placebo: treatment outcome score at 4 hours in the trial funded by Dyax
“The median treatment outcome score at 4 hours was 50.0 in the ecallantide group and 0.0 in the placebo group (interquartile range [IQR], 0.0 to 100.0 in both groups; P=0.004).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated time to significant improvement was 165 minutes with ecallantide versus more than 240 minutes with placebo (P=0.14).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by Dyax; ClinicalTrials.gov number, NCT00262080.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide compared with placebo: change in mean symptom complex severity score at 4 hours
“Mean (SD) change from baseline in mean symptom complex severity score 4 hours after dosing was significantly greater with ecallantide use (-0.8 [0.6]) compared with placebo use (-0.4 [0.8]) (P = .01 comparing distributions).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The benefit of ecallantide was apparent within 2 hours after dosing and was maintained through 24 hours after dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide: guideline position as a second-line option
“However, concerns about a 3%-4% risk of potentially serious hypersensitivity reactions, including anaphylaxis, led the manufacturer to withdraw its application in Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite this, it remains approved by the US Food and Drug Administration (FDA) for administration exclusively by healthcare providers in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest considering ecallantide as a second-line option for ODT for HAE attacks only when first-line therapies are not available or feasible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote